Loss of suppressors of cytokine signaling 3 promotes aggressiveness in hepatocellular carcinoma

Journal of Investigative Surgery

Volumn 27, Issue 4, 2014, Pages 197-204

  Wu, Wen Yong ^a   Kim, Hyunchul ^b   Zhang, Chang Le ^a   Meng, Xiang Ling ^a   Wu, Zheng Sheng ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b Gachon University College of Medicine   (South Korea)

Author keywords

Hepatocellular carcinoma; SOCS3; STAT3

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4 [[(4 METHYLPHENYL)SULFONYLOXY]ACETAMIDO]SALICYLIC ACID; GELATINASE A; GELATINASE B; MYC PROTEIN; SMALL INTERFERING RNA; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; AMINOSALICYLIC ACID DERIVATIVE; BENZENESULFONIC ACID DERIVATIVE; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; SOCS3 PROTEIN, HUMAN; STAT3 PROTEIN, MOUSE; SUPPRESSOR OF CYTOKINE SIGNALING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LIVER CELL CARCINOMA; MOUSE; MTT ASSAY; NONHUMAN; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; CELL MOTION; HEPG2 CELL LINE; LIVER TUMOR; METABOLISM; RANDOMIZATION; TUMOR INVASION;

AMINOSALICYLIC ACIDS; ANIMALS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CELL MOVEMENT; CELL PROLIFERATION; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-MYC; RANDOM ALLOCATION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84903775940     PISSN: 08941939     EISSN: 15210553     Source Type: Journal    
DOI: 10.3109/08941939.2013.873098     Document Type: Article

References (49)

1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264-1273, e1261.
2. He J, Gu D, Wu X, et al. Major causes of death among men and women in China. N Engl J Med. 2005;353:1124-1134. (Pubitemid 41317435)
3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745-750. (Pubitemid 29114292)
4. McGlynn KA, Tsao L, Hsing AW, et al. International trends and patterns of primary liver cancer. Int J Cancer 2001;94:290-296. (Pubitemid 32911426)
5. Wu ZS, Cheng XW, Wang XN, et al. Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in human cutaneous melanoma. Melanoma Res. 2011;21:483-490.
6. Wu WY, Li J, Wu ZS, et al. Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in hepatocellular carcinoma. Exp Ther Med. 2011;2:647-653.
7. Wang Z, Zhu S, Shen M, et al. STAT3 is involved in esophageal carcinogenesis through regulation of Oct-1. Carcinogenesis 2013;34:678-688.
8. Bowman T, Garcia R, Turkson J, et al. STATs in oncogenesis. Oncogene 2000;19:2474-2488. (Pubitemid 30339203)
9. Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol. 1998;16:293-322. (Pubitemid 28183367)
10. O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368:161-170.
11. Calo V, Migliavacca M, Bazan V, et al. STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol. 2003;197:157-168. (Pubitemid 37485244)
12. Gao B,Wang H, Lafdil F, et al. STAT proteins - key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver. J Hepatol. 2012;57:430-441.
13. Wu WY, Li J, Wu ZS, et al. STAT3 activation in monocytes accelerates liver cancer progression. BMC Cancer 2011;11:506.
14. Alexander WS, Hilton DJ. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol. 2004;22:503-529. (Pubitemid 38680432)
15. Baltayiannis G, Baltayiannis N, Tsianos EV. Suppressors of cytokine signaling as tumor repressors. Silencing of SOCS3 facilitates tumor formation and growth in lung and liver. J BUON. 2008;13:263-265.
16. Huang WT, Yang SF, Wu CC, et al. Expression of signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 in urothelial carcinoma. Kaohsiung J Med Sci. 2009;25:640-646.
17. Ying M, Li D, Yang L, et al. Loss of SOCS3 expression is associated with an increased risk of recurrent disease in breast carcinoma. J Cancer Res Clin Oncol. 2010;136:1617-1626.
18. Wu ZS, Wang CQ, Xiang R, et al. Loss of miR-133a expression associated with poor survival of breast cancer and restoration of miR-133a expression inhibited breast cancer cell growth and invasion. BMC Cancer 2012;12:51.
19. Song S, Lippman SM, Zou Y, et al. Induction of cyclooxygenase-2 by benzo[a]pyrene diol epoxide through inhibition of retinoic acid receptor-beta 2 expression. Oncogene 2005;24:8268-8276. (Pubitemid 43250919)
20. Fan Y, Boivin GP, Knudsen ES, et al. The aryl hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis. Cancer Res. 2010;70:212-220.
21. Vesselinovitch SD, Mihailovich N. Kinetics of diethylnitrosamine hepatocarcinogenesis in the infantmouse. Cancer Res. 1983;43:4253-4259.
22. Choi JH, Ahn MJ, Park CK, et al. Phospho-Stat3 expression and correlation with VEGF, p53, and Bcl-2 in gastric carcinoma using tissue microarray. APMIS 2006;114:619-625.
23. Hoikkala S, Paakko P, Soini Y, et al. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2-complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma. Cancer Lett. 2006;236:125-132.
24. Flikkema RM, Toledo AH, Anaya-Prado R, et al. Principles of statistics in surgery. J Invest Surg. 2011;24:237-242.
25. Leber MF, Efferth T. Molecular principles of cancer invasion and metastasis (review). Int J Oncol. 2009;34:881-895.
26. Li L, Gao Y, Zhang LL, et al. Concomitant activation of the JAK/STAT3 and ERK1/2 signaling is involved in leptinmediated proliferation of renal cell carcinoma Caki-2 cells. Cancer Biol Ther. 2008;7:1787-1792.
27. Yu LF, Cheng Y, Qiao MM, et al. Activation of STAT3 signaling in human stomach adenocarcinoma drug-resistant cell line and its relationship with expression of vascular endothelial growth factor. World J Gastroenterol. 2005;11:875-879. (Pubitemid 40298092)
28. Kusaba T, Nakayama T, Yamazumi K, et al. Expression of p- STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol. 2005;58:833-838. (Pubitemid 41113390)
29. Sriuranpong V, Park JI, Amornphimoltham P, et al. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res. 2003;63:2948-2956. (Pubitemid 36667168)
30. Niu G, Bowman T, Huang M, et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002;21:7001-7010. (Pubitemid 35252974)
31. Mora LB, Buettner R, Seigne J, et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 2002;62:6659-6666. (Pubitemid 35364135)
32. Frank DA, Mahajan S, Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest. 1997;100:3140-3148. (Pubitemid 28022852)
33. Zhang Q, Nowak I, Vonderheid EC, et al. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large Tcell lymphoma and Sezary syndrome. Proc Natl Acad Sci USA 1996;93:9148-9153.
34. Weber-Nordt RM, Egen C, Wehinger J, et al. Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)- related lymphoma cell lines. Blood 1996;88:809-816. (Pubitemid 26333300)
35. Sanchez A, Nagy P, Thorgeirsson SS. STAT-3 activity in chemically induced hepatocellular carcinoma. Eur J Cancer. 2003;39:2093-2098. (Pubitemid 37297767)
36. Calvisi DF, Ladu S, Gorden A, et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006;130:1117-1128.
37. Bromberg JF,Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell 1999;98:295-303. (Pubitemid 29380565)
38. Yang SF, Yeh YT, Wang SN, et al. SOCS-3 is associated with vascular invasion and overall survival in hepatocellular carcinoma. Pathology 2008;40:558-563.
39. Bard-Chapeau EA, Li S, Ding J, et al. Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell. 2011;19:629-639.
40. Basu A, Meyer K, Lai KK, et al. Microarray analyses and molecular profiling of Stat3 signaling pathway induced by hepatitis C virus core protein in human hepatocytes. Virology 2006;349:347-358. (Pubitemid 43782881)
41. Christodoulidis G, Tsilioni I, Spyridakis ME, et al. Matrix metaloproteinase-2 and -9 serum levels as potential markers of intraperitoneal adhesions. J Invest Surg. 2013;26:134-140.
42. Gullu IH, Kurdoglu M, Akalin I. The relation of gelatinase (MMP-2 and -9) expression with distant sitemetastasis and tumour aggressiveness in colorectal cancer. Br J Cancer. 2000;82:249. (Pubitemid 30008993)
43. Chen R, Cui J, Xu C, et al. The significance of MMP-9 over MMP-2 in HCC invasiveness and recurrence of hepatocellular carcinoma after curative resection. Ann Surg Oncol. 2012;19(Suppl 3):S375-S384.
44. Wu X, YanQ, Zhang Z, et al.Acrp30 inhibits leptin-induced metastasis by downregulating the JAK/STAT3 pathway via AMPK activation in aggressive SPEC-2 endometrial cancer cells. Oncol Rep. 2012;27:1488-1496.
45. Kobayashi N, Uemura H, Nagahama K, et al. Identification of miR-30d as a novel prognostic maker of prostate cancer. Oncotarget 2012;3:1455-1471.
46. Syed ZA, Yin W, Hughes K, et al. HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop. BMC Cancer 2011;11:180.
47. Senft C, Priester M, Polacin M, et al. Inhibition of the JAK- 2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells. J Neurooncol. 2011;101:393-403.
48. Hsu CP, Chen YL, Huang CC, et al. Anti-interleukin- 6 receptor antibody inhibits the progression in human colon carcinoma cells. Eur J Clin Invest. 2011;41:277- 284.
49. Landen CN, Jr., Lin YG, Armaiz Pena GN, et al. Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Res. 2007;67:10389-10396. (Pubitemid 350070814)